The JAK2 46/1 haplotype in splanchnic vein thrombosis

Blood

Volumn 117, Issue 21, 2011, Pages 5777-5778

  Kouroupi, Eirini ^a   Kiladjian, Jean Jacques ^a   Chomienne, Christine ^a   Dosquet, Christine ^a   Bellucci, Sylvia ^b   Valla, Dominique ^c   Cassinat, Bruno ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

CONTROLLED STUDY; DNA DETERMINATION; FEMALE; HAPLOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPLANCHNIC BLOOD FLOW; VEIN THROMBOSIS;

EID: 79957616966     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-343657     Document Type: Letter

References (10)

1. Smalberg JH, Koehler E, Murad SD, et al. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood. 2011;117(15):3968-3973.
2. Olcaydu D, Harutyunyan A, Jäger R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450-454.
3. Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455-459.
4. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446-449.
5. Olcaydu D, Skoda RC, Looser R, et al. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia. 2009;23(10):1924-1926.
6. Jones AV, Campbell PJ, Beer PA, et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010;115(22):4517-4523.
7. Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010;24(1):105-109.
8. Guglielmelli P, Biamonte F, Spolverini A, et al. Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia. 2010;24(8):1533-1537.
9. Trifa AP, Cucuianu A, Petrov L, et al. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms. Ann Hematol. 2010;89(10):979-983.
10. Kiladjian J-J, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111(10):4922-4929.